Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study

BACKGROUND: Neoadjuvant therapy is recommended to improve the prognosis of oesophageal squamous cell carcinoma (ESCC). As a PD-1 inhibitor developed in China, camrelizumab is more accessible and available for Chinese ESCC patients. Camrelizumab plus neoadjuvant chemotherapy has shown promising effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Rui-Qin, Luo, Jun, Li, Lin-Jun, Du, Ming, Wu, Qing-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170768/
https://www.ncbi.nlm.nih.gov/pubmed/37161374
http://dx.doi.org/10.1186/s12893-023-02023-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170768/
https://www.ncbi.nlm.nih.gov/pubmed/37161374
http://dx.doi.org/10.1186/s12893-023-02023-5

Ejemplares similares